An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering Treatments

Allergan

Status: Completed

Conditions: Ocular Hypertension; Glaucoma, Open-Angle

Treatments: Drug: Prostaglandin Analogue -Containing IOP-Lowering Therapy

Study type: Observational

Funder types: Industry

Identifiers

NCT01735214

MAF/AGN/OPH/GLA/037

Details and patient eligibility

About

This study is a prospective, observational study of changing from any IOP-lowering treatment to a prostaglandin analogue-containing IOP-lowering medication for patients with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT). The decision to change medications lies with the physician according to their standard practice.

Enrollment: 358 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of primary open angle glaucoma (POAG) or ocular hypertension (OHT)
• Previously prescribed any IOP-lowering therapy which has been stopped and a new prostaglandin analogue -containing IOP-lowering therapy started

Exclusion criteria

• None

Trial design

358 participants in 1 patient group

Patients with POAG or OHT

Description:

Patients with POAG or OHT on current IOP-lowering therapy who are prescribed a prostaglandin analogue -containing IOP-lowering therapy by the physician. The decision to prescribe a change in IOP-lowering therapy lies with the physician according to their standard practice.

Treatment:

Drug: Prostaglandin Analogue -Containing IOP-Lowering Therapy